This study could significantly impact BioNTech’s stock performance and investor sentiment, especially if the results demonstrate a breakthrough in breast cancer treatment. The involvement of ...

On August 1, 2025, a UK Court of Appeal upheld the validity of Moderna’s European Patent No. 3,590,949 (“EP’949”) in a dispute with Pfizer ...

The completion of this study could positively impact Pfizer and BioNTech’s stock performance, as successful results may lead to new vaccine offerings, enhancing their market position. This development ...

Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

COVID-19 activity is rising in much of the country. Data shows overall respiratory virus spread is very low in the U.S.

Roivant Sciences Ltd.'s Vant model offers risk-isolated growth and monetization flexibility. Click for key ROIV drivers ...